Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INSM, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA | Options-implied move |
|---|---|---|---|---|---|
| 2027-01-28 | ARIKAYCE | Mycobacterium avium complex lung disease | sNDA | 86% | ±21% by Feb 19 |
Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Amikacin FDA approved Sep 2018 · Arikayce Kit |
NTM Lung Infection Due to MAC | Phase 3 · NCT02628600 | Completed |
| Brensocatib (INS1007) FDA approved Aug 2025 · Brinsupri |
Non-Cystic Fibrosis Bronchiectasis | Phase 3 · NCT04594369 | Completed |
| Treprostinil Palmitil Inhalation Powder | Pulmonary Arterial Hypertension | Phase 3 · NCT07481981 | Recruiting |
| Ethambutol | Mycobacterium Infections, Nontuberculous | Phase 3 · NCT04677569 | Completed |
| Liposomal amikacin for inhalation (Arikayce™)… | Pseudomonas Aeruginosa Infection | Phase 3 · NCT01315678 | Completed |
| C-C Motif Chemokine 19 | Mycobacterium Infections, Nontuberculous | Phase 3 · NCT04677543 | Completed |
| multi-drug regimen | NTM Lung Infection Due to MAC | Phase 3 · NCT02628600 | Completed |
| Tobramycin inhalation solution using a PARI LC®… | Pseudomonas Aeruginosa Infection | Phase 3 · NCT01315678 | Completed |
| Treprostinil Palmitil | Pulmonary Arterial Hypertension | Phase 2/3 · NCT05649748 | Active not recruiting |
| OpSCF | Atopic Dermatitis | Phase 2 · NCT06101823 | Completed |
| Mometasone Furoate Nasal Spray, 50 mcg | Chronic Rhinosinusitis Without Nasal Polyps | Phase 2 · NCT06013241 | Completed |
| rhIGF-I/rhIGFBP-3 | Myotonic Dystrophy Type 1 | Phase 2 · NCT00577577 | Completed |
| INS1033 | Healthy Volunteers | Phase 1 · NCT07765706 | Recruiting |
| [14C]-brensocatib | Healthy Volunteers | Phase 1 · NCT05652257 | Completed |
| TPIP F3 | Healthy Volunteers | Phase 1 · NCT07102316 | Completed |
| TPIP F2 | Healthy Volunteers | Phase 1 · NCT07102316 | Completed |
Also used in these trials (approved or third-party drugs, not INSM's own candidates): Azithromycin, Treprostinil, Rifampin, Midazolam Hydrochloride, Clarithromycin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INSM holds $1.1B in cash and short-term investments (as of Sep 30, 2026) and burns about $62.6M/quarter from operations, an estimated runway of 54.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INSM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 16,127,583 | 7.35% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 14,121,445 | 6.44% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 11,514,893 | 5.25% | 2026-03-31 |
| Vanguard Portfolio Management LLC | Institution (13F) | 10,529,985 | 4.80% | 2026-09-30 |
| Capital International Investors | Institution (13F) | 9,352,633 | 4.26% | 2026-09-30 |
| Baker Bros. Advisors, LP | Institution (13F) | 8,796,111 | 4.01% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 8,243,537 | 3.76% | 2026-09-30 |
| Orbis Allan Gray Ltd | Institution (13F) | 6,733,982 | 3.07% | 2026-09-30 |
| Ameriprise Financial, Inc. | Institution (13F) | 6,251,016 | 2.85% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 6,162,413 | 2.81% | 2026-09-30 |
| William Lewis Chair and CEO, Director |
Insider | 492,982 | 0.22% | 2026-07-23 |
| Melvin Md Sharoky Director |
Insider | 267,901 | 0.12% | 2026-08-17 |
Share count 219,380,309 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-19 filed 2026-10-20 |
Koppikar Utpal |
Award (A) | 6,139 | – | 6,139 |
| 2026-10-19 filed 2026-10-20 |
Hudson Paul |
Award (A) | 6,139 | – | 6,139 |
| 2026-09-09 filed 2026-09-11 |
Brennan David R |
Sale (S) | 25,000 | $124.00 | 39,238 |
| 2026-08-17 filed 2026-08-19 |
SHAROKY MELVIN MD |
Sale (S) | 5,000 | $127.53 | 0 |
| 2026-08-10 filed 2026-08-12 |
Adsett Roger |
Option exercise (M) | 80,970 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INSM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →